An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii
Krakow, Poland
- Samodzielny Publiczny Szpital Kliniczny
Lublin, Poland
- Instytut Hematologii I Transfuzjologii
Warsaw, Poland
- Ucla Healthcare Hematology-Oncology
Santa Monica, California, United States
- University of Louisville
Louisville, Kentucky, United States
- New York Oncology Hematology Pc.
Clifton Park, New York, United States
- Tennessee Oncology
Nashville, Tennessee, United States
- University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
- Renovatio Clinical Consultants Llc
The Woodlands, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2016
- Primary completion
- 30 Sept 2027
- Completion
- 30 Sept 2027
- Last update posted
- 17 Dec 2025
- Registered enrollment
- 10
- Registry id
- NCT02955940
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.